Acquisitions and Other Transactions (Other Transactions) (Narrative) (Details) $ / shares in Units, shares in Millions, $ in Millions				1 Months Ended	2 Months Ended	3 Months Ended	12 Months Ended
	Nov. 07, 2022 USD ($)	Nov. 13, 2020 USD ($) shares	Jul. 29, 2019 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2020 USD ($)	Mar. 31, 2023 USD ($) right $ / shares	Dec. 31, 2022 USD ($) market	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Nov. 16, 2020 USD ($)
Business Acquisition [Line Items]
Contingent consideration liability				$ 223.6	$ 223.6		$ 375.0	$ 199.7	$ 223.6
Equity securities							42.6	51.0
Goodwill				12,347.0	12,347.0		10,425.8	12,113.7	12,347.0
Famy Life Sciences
Business Acquisition [Line Items]
Equity securities				$ 25.0	$ 25.0				$ 25.0
Subsequent Event | Famy Life Sciences
Business Acquisition [Line Items]
Gain (Loss) on Sale of Equity Investments						$ 18.9
Viatris Inc. | Famy Life Sciences
Business Acquisition [Line Items]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners				13.50%	13.50%				13.50%
Machinery and equipment
Business Acquisition [Line Items]
Acquired intangible assets, weighted average useful life, in years		5 years
Finite-Lived Intangible Assets
Business Acquisition [Line Items]
Acquired intangible assets, weighted average useful life, in years		15 years
Maximum | Building
Business Acquisition [Line Items]
Acquired intangible assets, weighted average useful life, in years		20 years
Minimum | Building
Business Acquisition [Line Items]
Acquired intangible assets, weighted average useful life, in years		10 years
Upjohn Inc.
Business Acquisition [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired			43.00%
Long-term debt, including current portion							$ 13,076.2	13,076.2
Shares issued in Combination | shares		689.9
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable		$ 10,730.0
Business Combination, Acquisition Related Costs								234.6	$ 602.9
Number Of Markets | market							165
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory		1,430.0					$ (34.2)
Amortization of Inventory Step Up							1,190.0	238.2
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Property, Plant, and Equipment		385.0					(5.0)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		18,040.0					18,040.0	18,040.0
Goodwill		2,400.0					2,403.1	$ 2,107.5
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Long-Term Debt		$ 759.4
Business Acquisition, Pro Forma Revenue					$ 866.5		18,284.8
Business Acquisition, Pro Forma Net Income (Loss)					$ 360.9		$ 1,483.7
Oyster Point Pharma, Inc. | Subsequent Event
Business Acquisition [Line Items]
Business Acquisition, Share Price | $ / shares						$ 11
Business Acquisition, Non-Transferable Contingent Value Right, Number Of Rights | right						1
Business Acquisition, Contingent Consideration Per Share | $ / shares						$ 2
Oyster Point Pharma, Inc. | Subsequent Event | Scenario, Forecast
Business Acquisition [Line Items]
Acquisition purchase price						$ 425.0
Contingent consideration liability						$ 60.0
Famy Life Sciences
Business Acquisition [Line Items]
Acquisition purchase price	$ 281.0
Net sales | Upjohn Inc.
Business Acquisition [Line Items]
Number Of Products			20
Pfizer, Inc.
Business Acquisition [Line Items]
Inventory, Firm Purchase Commitment, Loss				$ 86.5
Pfizer, Inc. | Upjohn Inc.
Business Acquisition [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent			57.00%
Upjohn Inc. | Pfizer, Inc.
Business Acquisition [Line Items]
Payments for Business Separation			$ 12,000.0
Long-term debt, including current portion										$ 13,080.0